Psychedelic-assisted therapy: where it actually stands

Where it stands

Strip away the coverage and the position is simple. As of July 2026, no classic psychedelic-assisted therapy is approved by the FDA for any psychiatric indication. Not MDMA, not psilocybin, not LSD. What exists is a set of late-stage programs, one high-profile rejection, and a set of state-level frameworks that operate outside the federal approval pathway entirely.

That last point is the one people miss. A state can create a supervised-use program without the FDA approving anything, and some have. Legal availability under a state program and FDA approval as a medicine are entirely different things, and conflating them is the single most common error in this conversation.

What actually happened with MDMA

In 2024 the FDA reviewed MDMA-assisted therapy for PTSD. An advisory committee voted against it, and the agency issued a Complete Response Letter in August of that year.

Read the objections carefully, because they're widely misreported in both directions. Advocates said the FDA was hostile to psychedelics. Skeptics said the drug had been shown not to work. Neither is what the record says. The concerns were about how the trials were run: functional unblinding, questions about how the therapy component was standardized and measured, and allegations of misconduct at a trial site that cast doubt on data integrity.

That's a rejection of an evidence package, not a verdict on a molecule. It's also a harder problem to fix than a failed endpoint, because it goes to whether the field can produce trials anyone can trust.

The blinding problem is real, and it isn't going away

Here's the methodological knot, and it deserves to be stated plainly rather than waved past.

In a trial of a drug that produces a profound, unmistakable subjective experience, participants know which arm they're in. So do the therapists in the room. Expectancy is enormous in this population, the participants are often people who sought out the trial specifically because they believe in the treatment, and the outcome is a self-reported symptom scale. Every one of those factors pushes in the same direction.

None of that means the effect isn't real. It means we can't yet measure how much of it is the drug. That's a legitimate scientific problem, and the profession does itself no favors by treating people who raise it as obstructionists.

Psilocybin

Psilocybin for depression is further along than most of the public discussion assumes and less settled than the enthusiasm implies. Programs hold Breakthrough Therapy designation, which is a signal that the FDA sees promise and will engage intensively, and which is routinely misreported as though it were approval. It isn't. Late-stage results have read out with real effects and real debate about magnitude and durability.

The honest summary is that this may well arrive, that it will arrive with a delivery model nobody has staffed for, and that the timeline is not knowable from here.

What this means for the profession

Three things, none of them exciting, all of them true.

First, if any of these are approved, the bottleneck won't be the drug. It'll be the therapy. These protocols involve many hours of trained clinician time per patient, which is a staffing and reimbursement model that essentially does not exist. A field that already can't staff a working insurance network is not obviously ready to deliver eight-hour supervised sessions.

Second, the thing psychiatry actually has to offer right now is honesty. Patients are asking, and the truthful answer is: promising, unapproved, and not yet measurable with confidence. That answer is less satisfying than either the hype or the dismissal, and it's the one that will age well.

Third, don't confuse this with esketamine, which is a distinct, approved, and tightly regulated treatment. See interventional psychiatry as a service line for what's actually deliverable today. Medication detail lives on PsychiatryRx, not here; shrinkiatry's lane is the profession and the system around it.